First-in-humans phase I trial of KU 5039

Trial Profile

First-in-humans phase I trial of KU 5039

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs KU 5039 (Primary)
  • Indications Insulin resistance; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Kareus Therapeutics
  • Most Recent Events

    • 18 Apr 2016 Status changed from not yet recruiting to recruiting, based on the information obtained from company website. (
    • 13 Feb 2014 New trial record
    • 11 Feb 2014 The FDA has approved this trial, according to a Kareus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top